newsfilter
← Latest News
ACCESS Newswire·

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Cash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly rangeCash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of VenoValve and the